• Product nameAnti-Osteoprotegerin antibody [98A1071]
    See all Osteoprotegerin primary antibodies
  • Description
    Mouse monoclonal [98A1071] to Osteoprotegerin
  • Specificityab11994 detects human osteoprotegerin.
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide, corresponding to amino acids 20-37 of Osteoprotegerin. (Human).

  • Positive control
    • Daudi whole-cell extract.


Associated products


Our Abpromise guarantee covers the use of ab11994 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 - 2 µg/ml. Detects a band of approximately 55 kDa (predicted molecular weight: 48.1 kDa). For optimal results, primary antibody incubations should be performed at room temperature.


  • FunctionActs as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
  • Tissue specificityHighly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
  • Involvement in diseaseDefects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.
  • Sequence similaritiesContains 2 death domains.
    Contains 4 TNFR-Cys repeats.
  • Post-translational
    N-glycosylated. Contains sialic acid residues.
    The N-terminus is blocked.
  • Cellular localizationSecreted.
  • Information by UniProt
  • Database links
  • Alternative names
    • MGC29565 antibody
    • OCIF antibody
    • OPG antibody
    • Osteoclastogenesis inhibitory factor antibody
    • Osteoprotegerin antibody
    • PDB5 antibody
    • TNF receptor superfamily member 11b antibody
    • TNFRSF 11B antibody
    • TNFRSF11B antibody
    • TR 1 antibody
    • TR1 antibody
    • TR11B_HUMAN antibody
    • Tumor necrosis factor receptor superfamily member 11B antibody
    see all

Anti-Osteoprotegerin antibody [98A1071] images

  • Predicted band size : 48.1 kDa

    OPG detection by Western blot. The analysis of Daudi cell extract for OPG using a dilution of 2 µg/ml. The immunoreactivity was detected by enhanced chemiluminescence.

References for Anti-Osteoprotegerin antibody [98A1071] (ab11994)

This product has been referenced in:
  • Larussa T  et al. No evidence of circulating autoantibodies against osteoprotegerin in patients with celiac disease. World J Gastroenterol 18:1622-7 (2012). WB ; Human . Read more (PubMed: 22529691) »
  • Riches PL  et al. Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. N Engl J Med 361:1459-65 (2009). Read more (PubMed: 19812402) »

See all 2 Publications for this product

Product Wall

There are currently no Abreviews or Questions for ab11994.
Please use the links above to contact us or submit feedback about this product.